Aquestive Therapeutics Inc (NASDAQ:AQST) price on Wednesday, April 30, rose 3.17% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.92.
A look at the stock’s price movement, the close in the last trading session was $2.84, moving within a range at $2.77 and $2.955. The beta value (5-Year monthly) was 2.591. Turning to its 52-week performance, $5.80 and $2.20 were the 52-week high and 52-week low respectively. Overall, AQST moved 0.86% over the past month.
Aquestive Therapeutics Inc’s market cap currently stands at around $290.51 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-04.
Analysts have a consensus estimate of 12.23M for the company’s revenue for the quarter, with a low and high estimate of 11.6M and 13M respectively. The average forecast suggests up to a 1.47% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 49.58M, representing a -13.87% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that AQST is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend AQST as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
AQST’s current price about 9.06% and 4.21% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.77, while 7-day volatility ratio is 5.64% and 7.98% in the 30-day chart. Further, Aquestive Therapeutics Inc (AQST) has a beta value of 2.02, and an average true range (ATR) of 0.19. Analysts have given the company’s stock an average 52-week price target of $8.5, forecast between a low of $7 and high of $10. Looking at the price targets, the low is -139.73% off current price level while to achieve the yearly target high, price needs to move -242.47%. Nonetheless, investors will most likely welcome a -191.1% jump to $8.5 which is the analysts’ median price.
If we refocus on Aquestive Therapeutics Inc (NASDAQ:AQST), historical trading data shows that trading volumes averaged 0.99 over the past 10 days and 1.57 million over the past 3 months. The company’s latest data on shares outstanding shows there are 91.41 million shares.
The 11.22% of Aquestive Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 38.87% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.87 million on 2025-04-15, giving us a short ratio of 7.1. The data shows that as of 2025-04-15 short interest in Aquestive Therapeutics Inc (AQST) stood at 1177.0 of shares outstanding, with shares short falling to 10.23 million registered in 2025-03-14. Current price change has pushed the stock -17.84% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AQST stock continues to rise going into the next quarter.
